Drugs / HR18034
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04551924 | Oct 2020 → May 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06509958 | Aug → Oct 2024 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05744674 | Feb → Jun 2023 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05561309 | Oct 2022 → Dec 2024 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05376904 | Jun → Oct 2022 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05769855 | Mar → Oct 2023 | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR18034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561309 ↗ |
| Known as | Ropivacaine | “HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome” NCT04551924 ↗ |
| Route | Other | “single injection adductor canal block with HR18034” NCT05561309 ↗ |